HUMAN MONOCLONAL ANTI CYTOMEGALOVIRUS ANTIBODY IN AIDS PATIENTS WITH CMV

人类单克隆抗巨细胞病毒抗体在患有巨细胞病毒的艾滋病患者中的应用

• 批准号: 6117780
• 负责人: MITCHELL GOLDMAN
• 金额: $ 1.7万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6117780
• 关键词: AIDS; clinical research; combination therapy; cytomegalovirus; cytomegalovirus retinitis; dosage; drug screening /evaluation; foscarnet; ganciclovir; human subject; human therapy evaluation; immunotherapy; microorganism disease chemotherapy; monoclonal antibody; placebos

This will be a Phase II, double-blinded, placebo-controlled, randomized clinical trial comparing the efficacy hanciclovir of foscarne alone with the efficacy of either drug comvined wiht on the two dose levels of MSL 109 for treatment and maintenance of CMV retinitis. Subjects will be randomized to one of three arms with approximately 56 subjects per arm.

这将是第二阶段，双盲，安慰剂对照，随机 汉昔洛韦单用福斯卡尼与汉昔洛韦疗效比较的临床试验 两种药物在两种剂量水平下的联合疗效 109，用于治疗和维持巨细胞病毒视网膜炎。主题将是 随机分为三组中的一组，每组约56名受试者。